Nalaganje...
Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics
Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In comparative trials, across dose ranges this statin reduced low-density lipoprotein (LDL) cholesterol and total chole...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2009
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108688/ https://ncbi.nlm.nih.gov/pubmed/21701608 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|